TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Sponsor

American Society of Clinical Oncology (Other)

Overall Status

Recruiting

CT.gov ID

NCT02693535

Collaborator

AstraZeneca (Industry), Bayer (Industry), Bristol-Myers Squibb (Industry), Eli Lilly and Company (Industry), Genentech, Inc. (Industry), Merck Sharp & Dohme LLC (Industry), Pfizer (Industry), Boehringer Ingelheim (Industry), Seagen Inc. (Industry)

3,581

Enrollment

126

Locations

Arms

117.6

Anticipated Duration (Months)

28.4

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

Condition or Disease	Intervention/Treatment	Phase
Lymphoma, Non-Hodgkin Multiple Myeloma Advanced Solid Tumors	Drug: Crizotinib Drug: Palbociclib Drug: Sunitinib Drug: Temsirolimus Drug: Trastuzumab and Pertuzumab Drug: Vemurafenib and Cobimetinib Drug: Regorafenib Drug: Olaparib Drug: Pembrolizumab Drug: Nivolumab and Ipilimumab Drug: Abemaciclib Drug: Afatinib Drug: Talazoparib Drug: Atezolizumab and PHESGO Drug: Atezolizumab and Talazoparib Drug: Entrectinib Drug: Larotrectinib Drug: Tucatinib plus Trastuzumab Subcutaneous (SC)	Phase 2

Detailed Description

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

3581 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Actual Study Start Date :

Mar 14, 2016

Anticipated Primary Completion Date :

Dec 31, 2024

Anticipated Study Completion Date :

Dec 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
Other: Group 3 (ALK, ROS1, MET) Participants receive crizotinib - dosage, frequency and duration per label; acceptable genomic matches include ALK fusion or mutation, ROS1 fusion, MET amplification or mutation, MET exon 14 alteration, RON amplification or mutation	Drug: Crizotinib drug Other Names: Xalkori
Other: Group 4 (CDKN2A, CDK4, CDK6) Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications	Drug: Palbociclib drug Other Names: Ibrance
Other: Group 5 (CSF1R,PDGFR,VEGFR) Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations	Drug: Sunitinib drug Other Names: Sutent
Other: Group 6 (mTOR, TSC) Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations	Drug: Temsirolimus drug Other Names: Torisel
Other: Group 8 (ERBB2) Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations	Drug: Trastuzumab and Pertuzumab drug Other Names: Herceptin and Perjeta
Other: Group 9 (BRAF V600E/D/K/R) Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations	Drug: Vemurafenib and Cobimetinib drug Other Names: Zelboraf and Cotellic
Other: Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF) Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications	Drug: Regorafenib drug Other Names: Stivarga
Other: Group 14 (BRCA1/2; ATM) Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions	Drug: Olaparib drug Other Names: Lynparza
Other: Group 15 (POLE, POLD1) Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations	Drug: Pembrolizumab drug Other Names: Keytruda
Other: Group 16 (MSI-H, high mutational load and others) Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations	Drug: Nivolumab and Ipilimumab drug Other Names: Opdivo and Yervoy
Other: Group 17 (CDKN2A, CDK4, CDK6) Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications	Drug: Abemaciclib drug Other Names: Verzenio
Other: Group 18 (NRG1) Participants receive afatinib - dosage, frequency and duration per label; acceptable genomic matches include NRG1 fusions	Drug: Afatinib drug Other Names: Gilotrif
Other: Group 19 (BRCA1/2, PALB2) Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations	Drug: Talazoparib drug Other Names: Talzenna
Other: Group 20 (ERBB2) Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression	Drug: Atezolizumab and PHESGO drug Other Names: Tecentriq and PHESGO
Other: Group 21 (BRCA1/2, PALB2, ATM, and others) Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test	Drug: Atezolizumab and Talazoparib drug Other Names: Tecentriq and Talzenna
Other: Group 22 (ROS1 fusion) Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion	Drug: Entrectinib drug Other Names: Rozlytrek
Other: Group 23 (NTRK amplification) Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification	Drug: Larotrectinib drug Other Names: Vitrakvi
Other: Group 24 (ERBB2) Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations	Drug: Tucatinib plus Trastuzumab Subcutaneous (SC) drug Other Names: Tukysa and Herceptin Hylecta

Outcome Measures

Primary Outcome Measures

Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria [Assessed at 16 weeks of treatment]
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.

Secondary Outcome Measures

Overall survival (OS) [Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years]
OS will be estimated using the Kaplan-Meier method

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:

Absolute neutrophil count ≥ 1.5 x 106/µl
Hemoglobin > 9.0 g/dl
Platelets > 75,000/µl
Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2

Patients must have disease that can be objectively measured by physicial or radiographic exam or evaluable disease (per RECIST v1.1 for solid tumor, Lugano criteria for non Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral computed tomography (CT) scan, Magnetic Resonance Imaging (MRI), or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patients who have assessable disease by physical or radiographic examination but do not meet these definitions of measurable disease are eligible and will be considered to have evaluable disease. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
Ability to understand and the willingness to sign a written informed consent/assent document.
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.

Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.

Exclusion Criteria:

Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
Patients with primary brain tumors or leptomeningeal metastases are excluded.
Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.

Note: there are additional exclusion criteria that may apply

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Alabama at Birmingham Comprehensive Cancer Center	Birmingham	Alabama	United States	35294
2	Cancer Treatment Centers of America-Phoenix	Phoenix	Arizona	United States	85338
3	Sutter Auburn	Auburn	California	United States	95602
4	Sutter Alta Bates	Berkeley	California	United States	94705
5	The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate	Los Angeles	California	United States	90025
6	Kaiser Permanente - Oakland Medical Center	Oakland	California	United States	94611
7	Sutter Palo Alto Medical Foundation: Palo Alto	Palo Alto	California	United States	94301
8	Kaiser Permanente - Roseville Medical Center	Roseville	California	United States	95661
9	Sutter Roseville	Roseville	California	United States	95661
10	Kaiser Permanente - Sacramento Medical Center	Sacramento	California	United States	95814
11	Sutter Sacramento	Sacramento	California	United States	95816
12	Kaiser Permanente - South San Francisco Medical Center	San Francisco	California	United States	94080
13	California Pacific Medical Center Research Institute	San Francisco	California	United States	94115
14	Kaiser Permanente - San Francisco Medical Center	San Francisco	California	United States	94115
15	Sutter Cancer Research Consortium	San Francisco	California	United States	94115
16	Kaiser Permanente - San Jose Medical Center	San Jose	California	United States	95119
17	Kaiser Permanente - San Leandro Medical Center	San Leandro	California	United States	94577
18	Kaiser Permanente - Santa Clara Medical Center	Santa Clara	California	United States	95051
19	Sutter Palo Alto Medical Foundation: Santa Cruz	Santa Cruz	California	United States	95065
20	Sutter Palo Alto Medical Foundation: Fremont	Santa Cruz	California	United States	994538
21	Sutter Palo Alto Medical Foundation: Sunnyvale	Sunnyvale	California	United States	94086
22	Kaiser Permanente - Vallejo Medical Center	Vallejo	California	United States	94589
23	Kaiser Permanente - Walnut Creek Medical Center	Walnut Creek	California	United States	94596
24	Saint Vincent's Medical Center (SVMC)	Bridgeport	Connecticut	United States	06606
25	Hartford Hospital	Hartford	Connecticut	United States	06002
26	Midstate Medical Center (MSMC)	Meriden	Connecticut	United States	06451
27	The Hospital of Central Connecticut (HOCC) Cancer Center	New Britain	Connecticut	United States	06053
28	William W. Backus Hospital	Norwich	Connecticut	United States	06360
29	Charlotte Hungerford	Torrington	Connecticut	United States	06790
30	Windham Hospital (WH)	Willimantic	Connecticut	United States	06226
31	Holy Cross Hospital	Fort Lauderdale	Florida	United States	33308
32	Florida Cancer Specialists South / Sarah Cannon Research Institute	Fort Myers	Florida	United States	33901
33	University of Florida Health	Gainesville	Florida	United States	32610
34	University of Miami Sylvester Comprehensive Cancer Center	Miami	Florida	United States	33136
35	Florida Cancer Specialists North / Sarah Cannon Research Institute	Saint Petersburg	Florida	United States	33705
36	Florida Cancer Specialists Panhandle / Sarah Cannon Research Institute	Tallahassee	Florida	United States	32308
37	Florida Cancer Specialists East / Sarah Cannon Research Institute	West Palm Beach	Florida	United States	33401
38	Cancer Treatment Centers of America - Atlanta	Atlanta	Georgia	United States	30265
39	Emory University Winship Cancer Institute	Atlanta	Georgia	United States	30322
40	Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion	Savannah	Georgia	United States	31405
41	Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute	Savannah	Georgia	United States	31405
42	Lewis Cancer & Research Pavilion	Savannah	Georgia	United States	31405
43	Summit Cancer Care	Savannah	Georgia	United States	31405
44	The Queen's Medical Center (The University of Texas MD Anderson Cancer Center)	Honolulu	Hawaii	United States	96813
45	Cancer Treatment Centers of America-Chicago	Chicago	Illinois	United States	60099
46	Community Health Network (The University of Texas MD Anderson Cancer Center)	Indianapolis	Indiana	United States	46250
47	Harold Alfond Center for Cancer Care	Augusta	Maine	United States	04330
48	Jackson Laboratory - Maine Cancer Genomics Initiative	Augusta	Maine	United States	04330
49	Waldo County General Hospital	Belfast	Maine	United States	04915
50	SMHC Cancer Care and Blood Disorders -Biddeford	Biddeford	Maine	United States	04005
51	Northern Light Cancer Care	Brewer	Maine	United States	04412
52	Raish Peavey Haskell Children's Cancer and Treatment Center	Brewer	Maine	United States	04412
53	MaineHealth Cancer Care -Brunswick	Brunswick	Maine	United States	04011
54	New England Cancer Specialist	Kennebunk	Maine	United States	04043
55	York Hopsital Oncology & Infusion Care in Kittery	Kittery	Maine	United States	03904
56	Stephens Memorial Hospital	Norway	Maine	United States	04268
57	Penobscot Bay Medical Center	Rockport	Maine	United States	04856
58	SMHC Cancer Care and Blood Disorders -Sandford	Sanford	Maine	United States	04073
59	Maine Children's Cancer Program	Scarborough	Maine	United States	04074
60	Maine Medical Partner's Women's Health	Scarborough	Maine	United States	04074
61	New England Cancer Specialist	Scarborough	Maine	United States	04074
62	MaineHealth Cancer Care -South Portland	South Portland	Maine	United States	04106
63	New England Cancer Specialist	Topsham	Maine	United States	04086
64	York Hospital Oncology & Infusion Care in Wells	Wells	Maine	United States	04090
65	York Hospital Oncology & Infusion Care in York	York	Maine	United States	03909
66	University of Michigan	Ann Arbor	Michigan	United States	48109
67	St. Joseph Mercy - Brighton	Brighton	Michigan	United States	48114
68	St. Joseph Mercy - Canton	Canton	Michigan	United States	48188
69	St. Joseph Mercy - Chelsea	Chelsea	Michigan	United States	48118-1370
70	Ascension St. John Hospital	Detroit	Michigan	United States	48236
71	Genesys Hurley Cancer Institute	Grand Blanc	Michigan	United States	48439
72	Cancer Research Consortium of West Michigan	Grand Rapids	Michigan	United States	49503
73	Ascension Borgess Cancer Center	Kalamazoo	Michigan	United States	49009
74	Sparrow Hospital	Lansing	Michigan	United States	48912
75	St. Mary Mercy Hospital	Livonia	Michigan	United States	48154
76	St. Joseph Mercy Hospital Oakland	Pontiac	Michigan	United States	48341
77	Ascension St. Mary's Hospital	Saginaw	Michigan	United States	48601
78	Michigan Cancer Research Consortium	Traverse City	Michigan	United States	48341
79	St. John Macomb Oakland Hospital	Warren	Michigan	United States	48093
80	University of Nebraska Medical Center	Omaha	Nebraska	United States	68198
81	NH Oncology - Hematology, PA	Concord	New Hampshire	United States	03103
82	Solinsky Center for Cancer Care	Manchester	New Hampshire	United States	03103
83	New England Cancer Specialist	Portsmouth	New Hampshire	United States	03801
84	Lovelace Medical Center - Saint Joseph Square	Albuquerque	New Mexico	United States	87102
85	Presbyterian Kaseman Hospital	Albuquerque	New Mexico	United States	87110
86	The University of New Mexico Comprehensive Cancer Center	Albuquerque	New Mexico	United States	87131
87	Memorial Medical Center	Las Cruces	New Mexico	United States	88011
88	Presbyterian Rust Medical Center	Rio Rancho	New Mexico	United States	87124
89	Northwell Health Monter Cancer Center	Lake Success	New York	United States	11042
90	Herbert Irving Comprehensive Cancer Center	New York	New York	United States	10032
91	Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina	United States	27599
92	Atrium Health's Levine Cancer Institute	Charlotte	North Carolina	United States	28277
93	Sanford Health- Bismarck	Bismarck	North Dakota	United States	58501
94	Sanford Health- Fargo	Fargo	North Dakota	United States	58122
95	University of Cincinnati Medical Center	Cincinnati	Ohio	United States	45219
96	Kettering Health	Kettering	Ohio	United States	45429
97	West Chester Hospital	West Chester	Ohio	United States	45069
98	Providence Health & Services	Portland	Oregon	United States	97213
99	Lehigh Valley Hospital	Allentown	Pennsylvania	United States	18105
100	Fox Chase Cancer Center	Philadelphia	Pennsylvania	United States	19111
101	SC Cancer Specialists at St. Joseph's/Candler Bluffton	Bluffton	South Carolina	United States	29910
102	St. Joseph's/Candler Smith	Bluffton	South Carolina	United States	29910
103	Summit Cancer Care at St. Josph's/Candler Bluffton	Bluffton	South Carolina	United States	29910
104	South Carolina Cancer Specialists	Hilton Head Island	South Carolina	United States	29926
105	Sanford Cancer Center Oncology Clinic and Pharmacy	Sioux Falls	South Dakota	United States	57104
106	Tennessee Oncology - Nashville / Sarah Cannon Research Institute	Nashville	Tennessee	United States	37203
107	The University of Texas MD Anderson Cancer Center	Houston	Texas	United States	77030
108	Intermountain Healthcare	Salt Lake City	Utah	United States	84107
109	Inova Schar Cancer Institute	Fairfax	Virginia	United States	22042
110	Swedish Cancer Institute	Seattle	Washington	United States	98104
111	Aurora Cancer Care - Burlington	Burlington	Wisconsin	United States	53105
112	Aurora Health Care - Germantown Health Center	Germantown	Wisconsin	United States	53022
113	Aurora Cancer Care - Grafton	Grafton	Wisconsin	United States	53024
114	Aurora BayCare Medical Center	Green Bay	Wisconsin	United States	54311
115	Aurora Cancer Care - Kenosha South	Kenosha	Wisconsin	United States	53142
116	Aurora Bay Area Medical Center	Marinette	Wisconsin	United States	54143
117	Aurora Cancer Care Milwaukee	Milwaukee	Wisconsin	United States	53209
118	Aurora St. Luke's Medical Center	Milwaukee	Wisconsin	United States	53215
119	Aurora Sinai Medical Center	Milwaukee	Wisconsin	United States	53223
120	Aurora West Allis Medical Center	Milwaukee	Wisconsin	United States	53227
121	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh	Wisconsin	United States	54904
122	Aurora Cancer Care - Racine	Racine	Wisconsin	United States	53406
123	Vince Lombardi Cancer Center	Sheboygan	Wisconsin	United States	53081
124	Aurora Medical Center in Summit	Summit	Wisconsin	United States	53066
125	Vince Lombardi Cancer Clinic - Two Rivers	Two Rivers	Wisconsin	United States	54241
126	Aurora Cancer Care - Milwaukee West	Wauwatosa	Wisconsin	United States	53226